Loading
Every dated change on the records linked to Oesophageal cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma
First-line HER2-positive gastric, gastro-oesophageal junction or oesophageal adenocarcinoma with tislelizumab and fluoropyrimidine-platinum chemotherapy
PFS and OS significantly improved at interim analysis (numbers presented ASCO 2026).
Co-primary endpoints including OS met (July 2026); numbers pending.
PFS 12.
OS and PFS significantly improved at interim analysis; numbers per ASCO 2026 presentation.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Perioperative FLOT improved overall survival compared with CROSS chemoradiotherapy in resectable oesophageal adenocarcinoma.
A milestone in how this cancer is treated.
First-line gastric or gastro-oesophageal junction adenocarcinoma with chemotherapy (ORIENT-16)
2-year OS non-inferior (HR 1.
A milestone in how this cancer is treated.
First-line oesophageal squamous cell carcinoma with chemotherapy (ORIENT-15)
OS 17.
OS 8.
OS 17.
A milestone in how this cancer is treated.
DFS 22.
PD-L1 ≥1%: OS 15.
OS 15.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Head and neck squamous cell carcinoma (CPS ≥1) and oesophageal squamous cell carcinoma (CPS ≥10)
Perioperative FLOT improved overall survival over ECF or ECX in resectable gastric and junctional adenocarcinoma.
A milestone in how this cancer is treated.